CONCENTRATION-EFFECT ANALYSIS OF ANTIHYPERTENSIVE DRUG RESPONSE - FOCUS ON CALCIUM-ANTAGONISTS

被引:13
作者
DONNELLY, R
ELLIOTT, HL
MEREDITH, PA
机构
[1] UNIV GLASGOW, DEPT MED & THERAPEUT, GLASGOW, SCOTLAND
[2] STANFORD UNIV, SCH MED,DEPT MED, PALO ALTO, CA 94304 USA
关键词
D O I
10.2165/00003088-199426060-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although individualised antihypertensive therapy is widely recommended, prospective methods for optimising treatment are hampered by the paucity of basic information about dose-plasma concentration-response relationships for commonly used drugs. Concentration-effect analysis has been applied to a number of therapeutic areas. With antihypertensive drugs this approach has clearly identified direct relationships between pharmacokinetic and pharmacodynamic profiles within individual patients. Thus, either a linear or nonlinear model can be used to quantify the antihypertensive drug response in terms of parameters that incorporate pharmacokinetic and pharmacodynamic information. Furthermore, these models take account of placebo effects and time-dependent changes in blood pressure and drug concentrations during a dosage interval. Concentration-effect analysis has been used to characterise the responses to a range of calcium antagonist drugs. These studies have demonstrated that these analyses are useful for optimising dosage schedules, identifying determinants of blood pressure response, and predicting steady-state profiles of blood pressure (including peak/trough effects) after administration of a single ('test') dose. This mode of analysis warrants early inclusion in the clinical development of any new antihypertensive agent, so that the familiar difficulties in identifying the optimum dosage range are avoided.
引用
收藏
页码:472 / 485
页数:14
相关论文
共 57 条
  • [1] EFFECTS OF AMLODIPINE, A LONG-ACTING DIHYDROPYRIDINE CALCIUM-ANTAGONIST IN AGING HYPERTENSION - PHARMACODYNAMICS IN RELATION TO DISPOSITION
    ABERNETHY, DR
    GUTKOWSKA, J
    WINTERBOTTOM, LM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) : 76 - 86
  • [2] PHARMACOKINETICS OF VERAPAMIL IN PATIENTS WITH HYPERTENSION
    ANDERSON, P
    BONDESSON, U
    DEFAIRE, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) : 155 - 163
  • [3] NIFEDIPINE IN THE TREATMENT OF HYPERTENSION - REPORT OF A DOUBLE-BLIND CONTROLLED TRIAL
    BAYLEY, S
    DOBBS, RJ
    ROBINSON, BF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 (04) : 509 - 512
  • [4] PLASMA-CONCENTRATION - EFFECT RELATIONSHIPS FOR FELODIPINE - A METAANALYSIS
    BLYCHERT, E
    EDGAR, B
    ELMFELDT, D
    HEDNER, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) : 80 - 89
  • [5] PLASMA-CONCENTRATION EFFECT RELATIONSHIPS OF INTRAVENOUS AND EXTENDED-RELEASE ORAL FELODIPINE IN HYPERTENSIVE PATIENTS
    BLYCHERT, E
    HEDNER, T
    DAHLOF, C
    ELMFELDT, D
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 (03) : 428 - 435
  • [6] BUHLER FR, 1985, J CARDIOVASCULAR PHA, V4, P535
  • [7] PHARMACOKINETICS, PHARMACODYNAMICS, AND MINIMUM EFFECTIVE CLINICAL DOSE OF INTRAVENOUS NICARDIPINE
    COOK, E
    CLIFTON, GG
    VARGAS, R
    BIENVENU, G
    WILLIAMS, R
    SAMBOL, N
    MCMAHON, G
    GRANDY, S
    LAI, CM
    QUON, C
    ANDERSON, CR
    TURLAPATY, P
    WALLIN, JD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (06) : 706 - 718
  • [8] AN EVALUATION OF THE PHARMACODYNAMICS AND PHARMACOKINETICS OF NICARDIPINE COMBINED WITH ENALAPRIL IN ESSENTIAL-HYPERTENSION
    DONNELLY, R
    ELLIOTT, HL
    MEREDITH, PA
    REID, JL
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1987, 10 (06) : 723 - 727
  • [9] NIFEDIPINE - INDIVIDUAL-RESPONSES AND CONCENTRATION-EFFECT RELATIONSHIPS
    DONNELLY, R
    ELLIOTT, HL
    MEREDITH, PA
    KELMAN, AW
    REID, JL
    [J]. HYPERTENSION, 1988, 12 (04) : 443 - 449
  • [10] KINETIC-DYNAMIC RELATIONS AND INDIVIDUAL-RESPONSES TO ENALAPRIL
    DONNELLY, R
    MEREDITH, PA
    ELLIOTT, HL
    REID, JL
    [J]. HYPERTENSION, 1990, 15 (03) : 301 - 309